TURNSTONE BIOLOGICS CORP (TSBX) Fundamental Analysis & Valuation

NASDAQ:TSBX • US90042W1009

Current stock price

0.355 USD
+0.01 (+1.43%)
Last:

This TSBX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. TSBX Profitability Analysis

1.1 Basic Checks

  • TSBX had negative earnings in the past year.
  • TSBX had a negative operating cash flow in the past year.
TSBX Yearly Net Income VS EBIT VS OCF VS FCFTSBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • TSBX has a worse Return On Assets (-228.20%) than 90.40% of its industry peers.
  • TSBX has a Return On Equity of -315.29%. This is in the lower half of the industry: TSBX underperforms 72.64% of its industry peers.
Industry RankSector Rank
ROA -228.2%
ROE -315.29%
ROIC N/A
ROA(3y)-84.15%
ROA(5y)N/A
ROE(3y)-108.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TSBX Yearly ROA, ROE, ROICTSBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TSBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSBX Yearly Profit, Operating, Gross MarginsTSBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TSBX Health Analysis

2.1 Basic Checks

  • TSBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TSBX has been reduced compared to 1 year ago.
  • TSBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TSBX Yearly Shares OutstandingTSBX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M
TSBX Yearly Total Debt VS Total AssetsTSBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -18.72, we must say that TSBX is in the distress zone and has some risk of bankruptcy.
  • TSBX's Altman-Z score of -18.72 is on the low side compared to the rest of the industry. TSBX is outperformed by 83.33% of its industry peers.
  • TSBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.72
ROIC/WACCN/A
WACC9.85%
TSBX Yearly LT Debt VS Equity VS FCFTSBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 3.70 indicates that TSBX has no problem at all paying its short term obligations.
  • TSBX has a Current ratio (3.70) which is comparable to the rest of the industry.
  • TSBX has a Quick Ratio of 3.70. This indicates that TSBX is financially healthy and has no problem in meeting its short term obligations.
  • TSBX has a Quick ratio of 3.70. This is comparable to the rest of the industry: TSBX outperforms 46.01% of its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.7
TSBX Yearly Current Assets VS Current LiabilitesTSBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TSBX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.43% over the past year.
  • The Revenue for TSBX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)41.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.91%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, TSBX will show a very strong growth in Earnings Per Share. The EPS will grow by 35.30% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y77.07%
EPS Next 2Y35.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TSBX Yearly Revenue VS EstimatesTSBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 20M 40M 60M 80M 100M
TSBX Yearly EPS VS EstimatesTSBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. TSBX Valuation Analysis

4.1 Price/Earnings Ratio

  • TSBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TSBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSBX Price Earnings VS Forward Price EarningsTSBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSBX Per share dataTSBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • TSBX's earnings are expected to grow with 35.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.3%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TSBX Dividend Analysis

5.1 Amount

  • No dividends for TSBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TSBX Fundamentals: All Metrics, Ratios and Statistics

TURNSTONE BIOLOGICS CORP

NASDAQ:TSBX (8/8/2025, 8:09:47 PM)

0.355

+0.01 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)N/A
Inst Owners39.89%
Inst Owner Change-100%
Ins Owners3.83%
Ins Owner ChangeN/A
Market Cap8.21M
Revenue(TTM)N/A
Net Income(TTM)-63.01M
Analysts43.33
Price Target1.02 (187.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.94%
Min EPS beat(2)-92.31%
Max EPS beat(2)20.43%
EPS beat(4)3
Avg EPS beat(4)-13.3%
Min EPS beat(4)-92.31%
Max EPS beat(4)20.43%
EPS beat(8)4
Avg EPS beat(8)-29.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-2.05
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.47
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -228.2%
ROE -315.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.15%
ROA(5y)N/A
ROE(3y)-108.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.7
Altman-Z -18.72
F-Score4
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)63.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.91%
EPS Next Y77.07%
EPS Next 2Y35.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.71%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.49%
OCF growth 3YN/A
OCF growth 5YN/A

TURNSTONE BIOLOGICS CORP / TSBX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TURNSTONE BIOLOGICS CORP (TSBX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TSBX.


What is the valuation status for TSBX stock?

ChartMill assigns a valuation rating of 1 / 10 to TURNSTONE BIOLOGICS CORP (TSBX). This can be considered as Overvalued.


How profitable is TURNSTONE BIOLOGICS CORP (TSBX) stock?

TURNSTONE BIOLOGICS CORP (TSBX) has a profitability rating of 0 / 10.


What is the expected EPS growth for TURNSTONE BIOLOGICS CORP (TSBX) stock?

The Earnings per Share (EPS) of TURNSTONE BIOLOGICS CORP (TSBX) is expected to grow by 77.07% in the next year.